Treatment Momentum Must Continue Despite Disappointing Trial Data

Treatment Momentum Must Continue Despite Disappointing Trial Data

Gantenerumab Phase 3 Trial Results Contribute Valuable Information for Additional Research

 Washington, D.C. (November 15, 2022) – Significant progress continues to be made in the effort to treat people in the early stages of dementia, despite disappointing news on Monday regarding Phase 3 clinical trials of gantenerumab. George Vradenburg, chair and co-founder of UsAgainstAlzheimer’s, issued the following statement regarding the urgent need for scientists, the federal government, and advocates to continue pushing forward in the fight to stop Alzheimer’s:

“A decade ago, our nation set a goal to prevent or treat Alzheimer’s by 2025 – with two years to go we are clearly behind and will have to keep our eyes on the ball if we hope to catch up. The latest data regarding gantenerumab cannot cast a shadow on the progress that is being made to slow the progress of dementia. In fact, it provides additional data that the science behind the ‘amyloid hypothesis’ remains sound and worthy of further exploration.

“We must also not forget the very promising trial results released in September regarding lecanemab. As we have said from the beginning, each one of these treatments work differently, which is why the research behind them must continue and why the federal government must evaluate each drug on its own merit as it considers FDA approval and Medicare coverage. In the meantime, advocates should keep up the pressure to ensure our nation remains laser-focused on meeting the 2025 goal by the next presidential inauguration.” 

# # #

About UsAgainstAlzheimer’s
UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. We take on the toughest problems; bring all of “Us” together to break down barriers; advocate for research that will speed treatments to market; and drive changes that matter most to people living with the disease. We will not rest until brain-span equals lifespan - for everyone.